Cargando…

A case series on tofacitinib-induced weight gain

Janus kinase inhibitor tofacitinib belongs to a group of targeted synthetic disease-modifying anti-rheumatic drugs, also known as small molecule inhibitors. They are oral drugs with a novel strategy to treat inflammatory diseases. The major concern with the use of these drugs is a high risk for infe...

Descripción completa

Detalles Bibliográficos
Autores principales: Shah, Kanisha, Shukla, Dhaiwat, Patel, Manish, Malhotra, Supriya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10657621/
https://www.ncbi.nlm.nih.gov/pubmed/37737080
http://dx.doi.org/10.4103/ijp.ijp_158_23
Descripción
Sumario:Janus kinase inhibitor tofacitinib belongs to a group of targeted synthetic disease-modifying anti-rheumatic drugs, also known as small molecule inhibitors. They are oral drugs with a novel strategy to treat inflammatory diseases. The major concern with the use of these drugs is a high risk for infections and other potential side effects. Here, we have focused on reporting one of the rare side effects of tofacitinib, weight gain. We have reported six cases of tofacitinib-induced weight gain in patients of ankylosing spondylitis, rheumatoid arthritis, and vasculitis.